Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 9/23/26 | Roche (RO) | RG6299 for Immunoglobulin A (IgA) Nephropathy (Berger's Disease) | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/22/26 | Roche (RO) | enicepatide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/22/26 | Roche (RO) | enicepatide for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/22/26 | VistaGen Therapeutics (VTGN) | fasedienol for Social Anxiety Disorder (SAD) | Subscribers Only | Subscribers Only | Subscribers Only |
| 9/15/26 | BioVie (BIVI) | bezisterim for COVID-19 Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 07/31/2025 | Subscribers Only | Subscribers Only | Regulatory - sNDA/sBLA Filing |
| 09/30/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Trial Completion |
| 10/28/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 10/31/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 11/11/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |